{"id":714688,"date":"2022-11-23T10:33:33","date_gmt":"2022-11-23T15:33:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/"},"modified":"2022-11-23T10:33:33","modified_gmt":"2022-11-23T15:33:33","slug":"g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/","title":{"rendered":"G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">RESEARCH TRIANGLE PARK, N.C., Nov.  23, 2022  (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1\u2019s Chief Executive Officer, and other members of the executive team will participate virtually in the Evercore ISI HealthCONx Conference. The fireside chat with G1 will be held at 1:25PM EST on November 30, 2022. The webcast and replay of this event will be accessible on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ed-_nSMT0ocDfmkP3zFh361keZmTPs3a1Db9sQnVAPLMzVBQefDkjk0vBIyBX7R5Ba6OqRz3k-re-krS3Xtaycnqg91ddEDTTP3-z2sa946isut6x7GUI1L1xgLj4LDSRcOIz9zwAWtZM07HCgrdxjXdXEgmhcktuWctfyhTce4=\" rel=\"nofollow noopener\" target=\"_blank\">Events &amp; Presentations page<\/a> of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qpLrqn4uCXC8dupt2cfOLKK-XKl7L8hc62Z4Lg77TbPxsjJ4dUu0iJzQeo7rviLeeg2KqiTME-DdONlX7Yw5o7kHfc6qPmX6vDfjtiVZTD4=\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/www.g1therapeutics.com<\/a>.<\/p>\n<p>\n        <strong>About G1 Therapeutics<\/strong><br \/>\n        <br \/>G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company\u2019s first commercial product, COSELA\u00ae (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating trilaciclib in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.<\/p>\n<p>G1 Therapeutics<sup>\u00ae<\/sup> and the G1 Therapeutics logo and COSELA<sup>\u00ae<\/sup> and the COSELA logo are trademarks of G1 Therapeutics, Inc.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>Will Roberts<br \/>Vice President, Investor Relations &amp; Corporate Communications<br \/>919-907-1944 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=15NYsMztFZjGtJYD6nAnodoxwmU0w9FdXiR5DL7d7jLwlcUHxds00bxj-mZynKH_xlH2AXsK_d_-eBlSCauziPdLVyYKOdq6hv7by8yoMcRKcrjPJHQIOWlul7BZuaUC\" rel=\"nofollow noopener\" target=\"_blank\">wroberts@g1therapeutics.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMjcwOSM1Mjc5NDI3IzIwMjkxMDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YWVjZDc3YzgtYzI4Yi00MDJkLWI0NzAtZWM2NTYyOTU1ODY2LTEwNDA2Nzg=\/tiny\/G1-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>RESEARCH TRIANGLE PARK, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1\u2019s Chief Executive Officer, and other members of the executive team will participate virtually in the Evercore ISI HealthCONx Conference. The fireside chat with G1 will be held at 1:25PM EST on November 30, 2022. The webcast and replay of this event will be accessible on the Events &amp; Presentations page of http:\/\/www.g1therapeutics.com. About G1 Therapeutics G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company\u2019s first commercial product, COSELA\u00ae (trilaciclib). G1 has a deep clinical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-714688","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RESEARCH TRIANGLE PARK, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1\u2019s Chief Executive Officer, and other members of the executive team will participate virtually in the Evercore ISI HealthCONx Conference. The fireside chat with G1 will be held at 1:25PM EST on November 30, 2022. The webcast and replay of this event will be accessible on the Events &amp; Presentations page of http:\/\/www.g1therapeutics.com. About G1 Therapeutics G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company\u2019s first commercial product, COSELA\u00ae (trilaciclib). G1 has a deep clinical &hellip; Continue reading &quot;G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-23T15:33:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMjcwOSM1Mjc5NDI3IzIwMjkxMDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference\",\"datePublished\":\"2022-11-23T15:33:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\\\/\"},\"wordCount\":217,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwMjcwOSM1Mjc5NDI3IzIwMjkxMDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\\\/\",\"name\":\"G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwMjcwOSM1Mjc5NDI3IzIwMjkxMDc=\",\"datePublished\":\"2022-11-23T15:33:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwMjcwOSM1Mjc5NDI3IzIwMjkxMDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwMjcwOSM1Mjc5NDI3IzIwMjkxMDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/","og_locale":"en_US","og_type":"article","og_title":"G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference - Market Newsdesk","og_description":"RESEARCH TRIANGLE PARK, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1\u2019s Chief Executive Officer, and other members of the executive team will participate virtually in the Evercore ISI HealthCONx Conference. The fireside chat with G1 will be held at 1:25PM EST on November 30, 2022. The webcast and replay of this event will be accessible on the Events &amp; Presentations page of http:\/\/www.g1therapeutics.com. About G1 Therapeutics G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company\u2019s first commercial product, COSELA\u00ae (trilaciclib). G1 has a deep clinical &hellip; Continue reading \"G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-11-23T15:33:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMjcwOSM1Mjc5NDI3IzIwMjkxMDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference","datePublished":"2022-11-23T15:33:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/"},"wordCount":217,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMjcwOSM1Mjc5NDI3IzIwMjkxMDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/","name":"G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMjcwOSM1Mjc5NDI3IzIwMjkxMDc=","datePublished":"2022-11-23T15:33:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMjcwOSM1Mjc5NDI3IzIwMjkxMDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMjcwOSM1Mjc5NDI3IzIwMjkxMDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-virtual-evercore-isi-healthconx-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/714688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=714688"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/714688\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=714688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=714688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=714688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}